U.S. firm founded by Ballari doctor imports NVIDIA DGX H100 to build world’s largest GenAI platform exclusively for health

To run the project, Vizzhy has imported the NVIDIA DGX H100, which claims to be the AI powerhouse and the foundation of NVIDIA DGX SuperPOD

November 08, 2023 12:56 pm | Updated November 10, 2023 02:52 pm IST - Bengaluru

Vizzhy’s a team of 40 data scientists, medical professionals and researchers and deep tech experts based in Bengaluru will be working on this project.

Vizzhy’s a team of 40 data scientists, medical professionals and researchers and deep tech experts based in Bengaluru will be working on this project. | Photo Credit: Photo for representation only

Texas-based Vizzhy Inc., a firm focussing on healthcare innovation leveraging multi-omics, is in the process of building what is claimed to be the world’s first and largest multi-omics-based Generative AI platform on holistic health to help the common man, medical professionals and researchers.

Vizzhy’s a team of 40 data scientists, medical professionals and researchers and deep tech experts based in Bengaluru will be working on this project. To run the project, the company has imported the NVIDIA DGX H100, which claims to be the AI powerhouse and the foundation of NVIDIA DGX SuperPOD, that helps enterprises solve the biggest challenges with AI through its high performance.

Multi-omics (multiple omics) offer possibilities of holistic discovery across multiple levels of biology. By combining multi-omics data, researchers will be able to get a deeper, holistic understanding of molecular changes happening in the human body, and therefore physicians would be able to treat all kinds of ailments more effectively with significantly less, but precise medication. Multi-omics involve a comprehensive analysis of biological data, integrating genomics, proteomics, transcriptomics, and metabolomics to unravel intricate disease mechanisms and advance personalised medicine.

Dr. Vishnu Vardhan Pogunulu Srinivasalu, founder of Vizzhy Inc., is an orthopaedics doctor hailing from Ballari district in Karnataka. He has an MS, and an MBA in Business Administration and Science & Technology from the Massachusetts Institute of Technology (MIT).

He told The Hindu, “What patients, especially the ones with multiple ailments, require is a holistic approach to understand their body and treat their complaints more effectively rather than treating patients with diverse medications prescribed by different specialists or super-specialists for different diseases triggered by metabolic issues.’‘

Quoting a 2019 National Health and Nutrition Examination Survey (NHANES) in the U.S., Dr. Srinivasalu said that some 88% of adults were metabolically unfit and the average adult gained 15 kg since the 1970s. A surge in metabolic diseases has propelled America’s annual healthcare spending to over $4 trillion, surpassing India’s GDP. Metabolic trends in India too were similar, or not satisfactory.

“This startling revelation prompted us to realise that the entire healthcare landscape required to be redefined. Transforming from specialists’ medication model to a holistic medication approach, a more natural way of treating diseases effectively,” he added.

Vizzhy’s Generative AI platform would be able to generate a humongous amount of innovative medical data, meant for the public and patients, medical fraternity and researchers, further expanding the possibilities of research and treatment for metabolic diseases.

“These technologies thrive on global collaboration, aggregating original research, expertise, datasets, and computational capabilities. Our attempt is set to explore novel avenues in the management of lifestyle ailments, and it is about taming the AI to tackle the root cause of metabolic diseases,’‘ Dr. Srinivasalu said.

Vizzhy’s approach focused on a systems biology paradigm, emphasising on preventative, predictive, precise, participatory (the patient has 70% of responsibility in managing his health, he argues), and personalised healthcare. The synergy of multi-omics and Generative AI is key to addressing the fundamental causes of metabolic diseases.

“Vizzhy Inc. is propelling a healthcare revolution by channelling the potent combination of multi-omics and Generative AI. The platform would respond to all health related queries from anyone, and generate authentic, well-researched medical data accordingly,: he elaborated.

Invests ₹100 crore on research in metabolic diseases 

To further its commitment to combat metabolic diseases through holistic approach, Vizzhy Inc has decided to invest over ₹100 crore ( $12.5 million) in Sreenivasulu AI for Wellness Centre, at the Grainger College of Engineering at the University of Illinois Urbana-Champaign.

This center, led by Prof. Narendra Ahuja, global scientist in Computer Vision, known for establishing India’s first IIIT in Hyderabad, would assemble a team of scientists, engineers, and health system experts committed to addressing one of humanity’s most pressing challenges — metabolic diseases. 

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.